Overview
|
During virus entry, involved in the transport of the viral pre-integration (PIC) complex to the nucleus (PubMed:12417576). This function is crucial for viral infection of non-dividing macrophages (PubMed:12417576). May act directly at the nuclear pore complex, by binding nucleoporins phenylalanine-glycine (FG)-repeat regions. During virus replication, may deplete host UNG protein, and incude G2-M cell cycle arrest(PubMed:7666531, PubMed:7474100). Acts by targeting specific host proteins for degradation by the 26S proteasome, through association with the cellular CUL4A-DDB1 E3 ligase complex by direct interaction with host VPRPB/DCAF-1. Cell cycle arrest reportedly occurs within hours of infection and is not blocked by antiviral agents, suggesting that it is initiated by the Vpr carried into the virion. Additionally, Vpr induces apoptosis in a cell cycle dependent manner suggesting that these two effects are mechanistically linked. Detected in the serum and cerebrospinal fluid of AIDS patient, Vpr may also induce cell death to bystander cells (PubMed:11000244).
|
Structure
|
Homooligomer, may form homodimer (PubMed:7798208). Interacts with p6-gag region of the Pr55 Gag precursor protein through a (Leu-X-X)4 motif near the C terminus of the P6gag protein (PubMed:7474102). Interacts with host UNG (PubMed:9151883). May interact with host RAD23A/HHR23A (PubMed:9371639). Interacts with host VPRBP/DCAF1, leading to hijack the CUL4A-RBX1-DDB1-DCAF1/VPRBP complex, mediate ubiquitination of host proteins such as TERT and ZGPAT and arrest the cell cycle in G2 phase (PubMed:17314515, PubMed:17630831, PubMed:17314515).
|
Alternative Nomenclature
|
DCAF1 antibody
DDB1 and CUL4 associated factor 1 antibody
HIV-1 Vpr-binding protein antibody
KIAA0800 antibody
protein VPRBP antibody
RIP antibody
Vpr (HIV-1) binding protein antibody
VPR BP antibody
Vpr interacting protein antibody
Vpr-binding protein antibody
|